DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Product Launch
Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development
- Aladdin has successfully released its proprietary AI Drug Discovery Platform to accelerate the drug development process.
- The automated machine learning platform pipeline covers main stages of early drug discovery: Virtual Screening, Hit to Lead known also as Lead Generation, Lead Optimisation and Preclinical Phase.
- With its proprietary platform, Aladdin has already identified and optimised multiple small molecule drug compounds with high potential for age-related diseases, including Alzheimer's disease, Parkinson's disease and SARS-CoV-2.
Aladdin's AI platform, by means of its groundbreaking components, such as ligand- and structure-based drug design using Artificial Intelligence (AI), can significantly speed up the process of drug development and even optimise new drug compounds. It generally takes 10 years to fully develop a new drug with a preclinical phase of 3 to 6 years. Thanks to Aladdin's AI platform, the preclinical phase can be reduced to half.
The platform can also help in the process of designing and generating new drug-like molecules based on the target structure or small molecule ligands. Aladdin's platform is therefore a relevant instrument for pharmaceutical companies, which can generate new compounds with annotated properties, such as ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity of the drug candidate), binding affinity and metabolic stability. In fact, the AIDD Platform acts like a big dynamic database, continuously kept updated with new data provided by Aladdin's partners and customers. In this way, the innovative Big Data technology connects findings and dynamizes the knowledge progress for the treatment of diseases.
Wade Menpes-Smith, CEO of Aladdin healthcare Technologies, comments: "Aladdin can now officially provide valuable solutions to the pharmaceutical industry via our proprietary AI Drug Discovery Platform that can accelerate the drug development process, covering the process of Virtual Screening, Hit to Lead and Lead Optimisation."
Aladdin is also working on several promising pipelines for the small molecule drug discovery in the early stage. Small molecule drugs are relatively simple chemical compounds. These compounds have a small molecular mass and their biggest advantage is the oral bioavailability. Already in May this year, Aladdin achieved two milestones in drug development against age-related diseases and COVID-19, by discovering new optimised compounds with its AIDD platform. The successful release of Aladdin's proprietary platform confirms again the capability of the Company to achieve groundbreaking milestones in the field of drug development. This opens the door to many relevant partnerships in the pharmaceutical industry.
About Aladdin Healthcare Technologies SE
For further information:
Aladdin Healthcare Technologies Ltd.
08.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
Aladdin Healthcare Technologies SE
Unter den Linden 10
Regulated Market in Dusseldorf
EQS News ID:
End of News
DGAP News Service